Clinical trialNCT04115306RecruitingPhase 1/PHASE2Interventional

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

SponsorPhoenix Molecular DesignsEnrollment61Metastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Hung T Khong, MD
Recruiting
City of Hope
Duarte, California, United States
Hope Rugo, MD
Recruiting
City of Hope Orange County, Lennar
Irvine, California, United States
Hope Rugo, MD
Recruiting
University of California, Los Angeles (ucla)
Los Angeles, California, United States
Nicolaos Palaskas, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Hyo Han, MD
Recruiting
City of Hope Chicago
Zion, Illinois, United States
Ajaz Khan, MD
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Seth Wander, MD
Recruiting
Profound Research
Farmington Hills, Michigan, United States
Jeffrey Margolis, MD
Recruiting
Ohio State University
Columbus, Ohio, United States
Robert Wesolowski, MD
Recruiting
Oncology Consultants
Houston, Texas, United States
Withdrawn
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Muralidhar Beeram, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PMD-026Fulvestrant →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Nov 2019
Primary completion: 30 Sept 2026
Completion: 31 Oct 2026
Last update posted: 21 Jan 2026
Registered enrollment: 61
Registry id: NCT04115306

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.